S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
Log in

TSE:INInMed Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
C$0.25
MA: C$2.07
C$9.19
52-Week Range N/A
Volume8,004 shs
Average Volume6,583 shs
Market CapitalizationC$44.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-669-7207

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC$1.85 per share

Profitability

Miscellaneous

Employees4
Market CapC$44.79 million
Next Earnings Date9/17/2020 (Estimated)
OptionableNot Optionable

Receive IN News and Ratings via Email

Sign-up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter.

InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of InMed Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMed Pharmaceuticals.

When is InMed Pharmaceuticals' next earnings date?

InMed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, September 17th 2020. View our earnings forecast for InMed Pharmaceuticals.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc (TSE:IN) issued its earnings results on Thursday, May, 14th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). View InMed Pharmaceuticals' earnings history.

Has InMed Pharmaceuticals been receiving favorable news coverage?

Press coverage about IN stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. InMed Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about InMed Pharmaceuticals.

Who are some of InMed Pharmaceuticals' key competitors?

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Canopy Growth (WEED), Cara Therapeutics (CARA), Hexo (HEXO), InMed Pharmaceuticals (IMLFF), Insys Therapeutics (INSY), Kirkland Lake Gold (KL), Lithium Americas (LAC), NVIDIA (NVDA) and Prophecy Development (PCY).

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs
  • Mr. Joshua Blacher, Chief Bus. Officer (Age 46)
  • Dr. Eric C. Hsu, Sr. VP of Preclinical R&D

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?

Shares of IN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is InMed Pharmaceuticals?

InMed Pharmaceuticals has a market capitalization of C$0.00. InMed Pharmaceuticals employs 4 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.